BeyondSpring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

16 Nov 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase... (more)


Beta: --
Market Cap(Mil.): $892.10
Shares Outstanding(Mil.): 22.84
Dividend: --
Yield (%): --


BRIEF-BeyondSpring qtrly loss per share $‍0.68

* BeyondSpring reports third quarter 2017 operational and financial results

09 Nov 2017

BRIEF-BeyondSpring announces first patient enrolled in China

* BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia

26 Oct 2017

BRIEF-China FDA approves ctas for Beyondspring's second global plinabulin registrational trial

* China FDA approves ctas for beyondspring’s second global plinabulin registrational trial for chemotherapy-induced neutropenia prevention

06 Jul 2017

BRIEF-BeyondSpring Q1 loss per share $2.66

* Beyondspring inc qtrly basic and diluted loss per share of $2.66

23 May 2017

Earnings vs. Estimates